<unk>  interacts strongly and in rare cases lethally with the anticancer drug fluorouracil (5-FU), its prodrugs and related substances. Even topically applied 5-FU can be dangerous in combination with<unk> . This is caused by the main metabolite, bromovinyluracil (BVU), irreversibly inhibiting the enzyme dihydropyrimidine dehydrogenase (DPD) which is necessary for inactivating 5-FU. After a standard<unk>  therapy, DPD function can be compromised for up to 18 days. This interaction is shared with the closely related drug sorivudine which also has BVU as its main metabolite. There are no other relevant interactions.<unk>  does not significantly influence the cytochrome P450 enzymes in the liver.
Brivudine
Fostemsavir
Censavudine
Saquinavir
Maribavir
Coronavir
Tipranavir
Stavudine